Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000069

Drug Information
SynonymsLopac0_000984; (8beta)-8-[(methylthio)methyl]-6-propylergoline; ST057534; Permax (TN); KBio2_002127; CHEBI:112494; CHEMBL531; NINDS_000442; SPBio_002099; KBio2_004695; LS-64479; KBio1_000442; BIDD:GT0177; NCGC00142538-03; C19H26N2S; KBioGR_001409; pergolide; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-; IDI1_000442; (6aR,9R,10aR)-9-(Methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline; MolPort-003-849-834; Permax; Pergolide [INN:BAN]; InChI=1/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s; nchembio873-comp45; KBioSS_002127; Pergolida [INN-Spanish]; LY-127,809; AC1L2IT3; BPBio1_000254; 66104-22-1; Spectrum4_000835; HMS2089C18; D08339; NCGC00142538-02; BPBio1_001211; C07425; Prestwick2_000295; Pergolidum; DB01186; Pergolide (INN); (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline; BSPBio_000230; SPBio_002449; 66104-23-2 (mesylate); AC1Q7DT2; Prestwick1_000295; DivK1c_000442; Spectrum2_001970; CID47811; Prestwick0_000295; BRD-K60770992-066-05-2; KBio2_007263; BSPBio_003156; UNII-24MJ822NZ9; NCGC00142538-01; Prestwick3_000295; Spectrum3_001588; Pergolidum [INN-Latin]; BRD-K60770992-001-01-8; Pergolida; NCGC00017366-05; Spectrum_001647; Biomol-NT_000025; Spectrum5_001649; KBio3_002656
CompanyValeant Pharmaceuticals
IndicationParkinson's disease
[ICD9: 332   ICD10: F02.3, G20]
Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Isomeric SMILESCCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
Therapeutic ClassAntiparkinson Agents
CAS NumberCAS 66104-22-1
PubChem Compound IDCID 47811.
PubChem Substance IDSID 9629.
SuperDrug ATC IDN04BC02
SuperDrug CAS ID066104221;
TargetD(2) dopamine receptorAgonist[2]
D(2) dopamine receptorMultitarget[2]
Dopamine D1 receptorAgonist[2]
Dopamine D1 receptorMultitarget[2]
Ref 1Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. To Reference
Ref 2Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia. 2009 Apr;47(5):1374-81. Epub 2009 Feb 7. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543